CO7081142A2 - Métodos de tratamiento de enfermedades de degeneración retiniana - Google Patents

Métodos de tratamiento de enfermedades de degeneración retiniana

Info

Publication number
CO7081142A2
CO7081142A2 CO14047158A CO14047158A CO7081142A2 CO 7081142 A2 CO7081142 A2 CO 7081142A2 CO 14047158 A CO14047158 A CO 14047158A CO 14047158 A CO14047158 A CO 14047158A CO 7081142 A2 CO7081142 A2 CO 7081142A2
Authority
CO
Colombia
Prior art keywords
cells
methods
retinal degeneration
treating retinal
degeneration diseases
Prior art date
Application number
CO14047158A
Other languages
English (en)
Spanish (es)
Inventor
Maria Pia Cosma
Daniela Sanges
Original Assignee
Maria Pia Cosma
Daniela Sanges
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Maria Pia Cosma, Daniela Sanges filed Critical Maria Pia Cosma
Publication of CO7081142A2 publication Critical patent/CO7081142A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0623—Stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/20—Milk; Whey; Colostrum
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/415—Wnt; Frizzeled

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Developmental Biology & Embryology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Virology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CO14047158A 2011-08-05 2014-03-05 Métodos de tratamiento de enfermedades de degeneración retiniana CO7081142A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP11176713A EP2554662A1 (en) 2011-08-05 2011-08-05 Methods of treatment of retinal degeneration diseases

Publications (1)

Publication Number Publication Date
CO7081142A2 true CO7081142A2 (es) 2014-10-10

Family

ID=46826437

Family Applications (1)

Application Number Title Priority Date Filing Date
CO14047158A CO7081142A2 (es) 2011-08-05 2014-03-05 Métodos de tratamiento de enfermedades de degeneración retiniana

Country Status (15)

Country Link
US (1) US20140199277A1 (https=)
EP (2) EP2554662A1 (https=)
JP (1) JP2014527407A (https=)
KR (1) KR20140068936A (https=)
CN (1) CN104011203A (https=)
AR (1) AR087471A1 (https=)
AU (1) AU2012293681A1 (https=)
BR (1) BR112014002718A8 (https=)
CA (1) CA2844106A1 (https=)
CO (1) CO7081142A2 (https=)
IL (1) IL230830A0 (https=)
MX (1) MX2014001475A (https=)
RU (1) RU2014108478A (https=)
SG (1) SG2014008080A (https=)
WO (1) WO2013020945A1 (https=)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103889441A (zh) 2011-09-29 2014-06-25 伊丽莎白女王在都柏林附近神圣不可分割的三一学院教务长、研究员、学者及董事会其他成员 用于治疗退行性视网膜病况的组合物和方法
AU2014378349B2 (en) 2014-01-17 2021-06-03 Riken Method for manufacturing ciliary margin stem cells
BR112017005235B1 (pt) * 2014-09-16 2023-10-31 Genzyme Corporation Vetores virais adeno-associados para o tratamento de glaucoma de miocilina (myoc)
RU2569481C1 (ru) * 2014-12-25 2015-11-27 федеральное государственное бюджетное учреждение "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова" Министерства здравоохранения Российской Федерации Способ получения культуры клеток ретинального пигментного эпителия из глаза взрослого донора-трупа
RU2578526C1 (ru) * 2014-12-25 2016-03-27 федеральное государственное бюджетное учреждение "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова" Министерства здравоохранения Российской Федерации Способ получения органной культуры хороидально-пигментного комплекса из глаза взрослого донора-трупа
KR101779932B1 (ko) * 2015-09-15 2017-09-21 주식회사 스템랩 나노그(Nanog)를 도입한 양수 내 태아 유래 중간엽 줄기세포를 이용한 육모 촉진용 조성물의 제조방법
CR20180323A (es) 2015-11-20 2018-08-06 Idorsia Pharmaceuticals Ltd Derivados de indol n-sustituídos como moduladores de los receptores de pge2
KR101674622B1 (ko) * 2016-07-07 2016-11-09 국민대학교산학협력단 세스퀴테르펜 유도체의 신규한 용도
WO2018034945A1 (en) * 2016-08-19 2018-02-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Selective estrogen-receptor modulators (serms) confer protection against photoreceptor degeneration
WO2018106369A2 (en) * 2016-11-06 2018-06-14 Nanoscope Technologies Llc Optogenetic modulation by multi-characteristic opsins for vision restoration and other applications thereof
JP2020518915A (ja) 2017-04-27 2020-06-25 パスハラキス スタブロスＰＡＳＣＨＡＬＡＫＩＳ， Ｓｔａｖｒｏｓ 自動眼底画像分析用のシステムおよび方法
PL3625228T3 (pl) 2017-05-18 2021-12-20 Idorsia Pharmaceuticals Ltd Pochodne pirymidyny jako modulatory receptora pge2
CN110621671A (zh) 2017-05-18 2019-12-27 爱杜西亚药品有限公司 作为pge2受体调节剂的苯并呋喃及苯并噻吩衍生物
EA201992676A1 (ru) 2017-05-18 2020-05-06 Идорсия Фармасьютиклз Лтд Фенильные производные в качестве модуляторов pge2 рецепторов
CN110621667A (zh) 2017-05-18 2019-12-27 爱杜西亚药品有限公司 嘧啶衍生物
EP3625224B1 (en) 2017-05-18 2021-08-04 Idorsia Pharmaceuticals Ltd N-substituted indole derivatives
WO2018232258A1 (en) * 2017-06-15 2018-12-20 University Of North Texas Health Science Center Reprogramming fibroblasts to retinal cells
CN117379543A (zh) * 2017-08-20 2024-01-12 加州大学董事会 治疗青光眼的Wnt5a的调节
WO2019195717A1 (en) * 2018-04-06 2019-10-10 Icahn School Of Medicine At Mount Sinai Compositions and methods of treatment of vision loss through generation of rod photoreceptors from müller glial cells
WO2020190848A1 (en) * 2019-03-15 2020-09-24 The Schepens Eye Research Institute, Inc. Isolation, enrichment and expansion of cone progenitor cells and uses thereof
CN110706164A (zh) * 2019-09-03 2020-01-17 北京爱博同心医学科技有限公司 基于增强现实的管状视野图像变形显示方法及眼镜
US12558336B2 (en) 2019-09-25 2026-02-24 The Board Of Trustees Of The Leland Stanford Junior University Metabolic rescue of retinal degeneration
KR20210119766A (ko) * 2020-03-25 2021-10-06 서울대학교병원 인간 배아줄기세포 유래 중간엽 줄기세포를 포함하는 망막색소변성의 예방 또는 치료용 약학적 조성물
KR102655748B1 (ko) * 2023-06-08 2024-04-05 충북대학교 산학협력단 고포도당 조건에서의 중간엽 줄기세포의 생존율을 증가시키는 방법
KR102655735B1 (ko) * 2023-06-09 2024-04-05 충북대학교 산학협력단 당뇨성 망막병증의 예방 및 치료를 위한 타크로리무스 전처리 줄기세포
WO2025229177A1 (en) 2024-05-02 2025-11-06 Idorsia Pharmaceuticals Ltd Crystalline forms of an n-substituted indole derivative

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6128654A (en) 1997-02-14 2000-10-03 Advanced Micro Devices, Inc. Method and apparatus for transmitting multiple copies by replicating data identifiers
US7045519B2 (en) 1998-06-19 2006-05-16 Chiron Corporation Inhibitors of glycogen synthase kinase 3
KR100581199B1 (ko) 1998-06-19 2006-05-17 카이론 코포레이션 글리코겐 신타제 키나제 3의 억제제
EP1237880B1 (en) 1999-12-17 2008-01-23 Novartis Vaccines and Diagnostics, Inc. Pyrazine based inhibitors of glycogen synthase kinase 3
CN100335479C (zh) 1999-12-17 2007-09-05 希龙公司 糖元合成酶激酶3的双环抑制剂
AU2001295026B2 (en) 2000-09-06 2008-04-03 Novartis Vaccines And Diagnostics, Inc. Inhibitors of glycogen synthase kinase 3
CZ304344B6 (cs) 2000-09-11 2014-03-19 Novartis Vaccines & Diagnostics, Inc. Chinolinonový derivát a jeho použití a farmaceutický prostředek s obsahem tohoto derivátu
CA2446756C (en) 2001-06-01 2011-03-08 Vertex Pharmaceuticals Incorporated Thiazole compounds useful as inhibitors of protein kinase
EP1472245A2 (en) 2002-02-06 2004-11-03 Vertex Pharmaceuticals Incorporated Heteroaryl compounds useful as inhibitors of gsk-3
US20050203059A1 (en) 2002-03-01 2005-09-15 Harrison Stephen D. Methods and compositions for treatment of ischemia
US7838290B2 (en) * 2002-07-25 2010-11-23 The Scripps Research Institute Hematopoietic stem cells and methods of treatment of neovascular eye diseases therewith
US20050129665A1 (en) * 2002-07-25 2005-06-16 Martin Friedlander Isolated lineage negative hematopoietic stem cells and methods of treatment therewith
AU2003268184A1 (en) 2002-08-23 2004-03-11 Chiron Corporation Pyrrole based inhibitors of glycogen synthase kinase 3
JP2006506383A (ja) 2002-10-21 2006-02-23 カイロン コーポレイション グリコーゲンシンターゼキナーゼ３のインヒビター
BRPI0409861A (pt) * 2003-05-02 2006-05-16 Scripps Research Inst células- tronco hematopoiéticas e sua utilização em métodos de tratamento de doenças oculares neovasculares
JP2007502300A (ja) 2003-08-13 2007-02-08 カイロン　コーポレイション Ｇｓｋ−３インヒビターおよびその使用
JP2008512376A (ja) * 2004-09-03 2008-04-24 ザ・スクリプス・リサーチ・インステイチユート 単離された系統陰性造血幹細胞及びこれを用いた治療方法
US7850960B2 (en) * 2004-12-30 2010-12-14 University Of Washington Methods for regulation of stem cells
AU2006216473B2 (en) 2005-02-24 2012-07-26 The Scripps Research Institute Method for the treatment of retinopathy of prematurity and related retinopathic diseases
US20070231306A1 (en) * 2005-02-24 2007-10-04 The Scripps Research Institute Isolated myeloid-like cell populations and methods of treatment therewith
CA2613889A1 (en) * 2005-06-08 2006-12-14 Centocor, Inc. A cellular therapy for ocular degeneration
NZ582616A (en) * 2007-06-15 2012-07-27 Garnet Biotherapeutics Inc Treatment of diseases and disorders using self-renewing colony forming cells cultured and expanded in vitro
EP2090649A1 (en) 2008-02-13 2009-08-19 Fondazione Telethon Method for reprogramming differentiated cells
GB0816577D0 (en) * 2008-09-11 2008-10-15 Axordia Ltd Growth factor
KR101268741B1 (ko) * 2009-10-06 2013-06-04 김지연 줄기세포를 망막세포로 분화시키는 방법

Also Published As

Publication number Publication date
AU2012293681A1 (en) 2014-03-06
RU2014108478A (ru) 2015-09-10
WO2013020945A1 (en) 2013-02-14
JP2014527407A (ja) 2014-10-16
MX2014001475A (es) 2014-07-22
US20140199277A1 (en) 2014-07-17
EP2554662A1 (en) 2013-02-06
AR087471A1 (es) 2014-03-26
CN104011203A (zh) 2014-08-27
WO2013020945A9 (en) 2013-04-04
IL230830A0 (en) 2014-03-31
CA2844106A1 (en) 2013-02-14
SG2014008080A (en) 2014-03-28
NZ621345A (en) 2015-09-25
EP2739723A1 (en) 2014-06-11
BR112014002718A8 (pt) 2017-06-20
BR112014002718A2 (pt) 2017-06-13
KR20140068936A (ko) 2014-06-09

Similar Documents

Publication Publication Date Title
CO7081142A2 (es) Métodos de tratamiento de enfermedades de degeneración retiniana
CY1123142T1 (el) Βελτιωμενες μεθοδοι για την παραγωγη θετων κυτταρικων θεραπειων
EA202090931A2 (ru) Композиции и способы перепрограммирования tcr с помощью гибридных белков
MX389160B (es) Células no t efectoras y madre/progenitoras hematopoyéticas modificadas y usos de estas.
GT201600007A (es) Derivados de piperidinil-indol como inhibidores del factor de complemento b y usos de los mismos
BR112017017886A2 (pt) gerando populações de células endoteliais arteriais
UY36171A (es) Derivados heteroaromáticos bicíclicos fusionados como inhibidores de quinasa
MX385585B (es) Anticuerpos anti-c10orf54 y usos de los mismos.
PH12018500609A1 (en) Method of redirecting t cells to treat hiv infection
MX2020001450A (es) Composiciones para reducir la inmunosupresion por celulas de tumor.
GT201400162A (es) Composición y método para el diagnóstico y el tratamiento de las enfermedades asociadas a la degeneración de las neuritas
UY33575A (es) Inmunoglobulinas con dominio variable dual y usos de las mismas
ECSP12012105A (es) Antídotos de Anticoagulantes
MX2016013635A (es) Métodos para aumentar los niveles de eritrocitos y tratar de la enfermedad de células falciformes.
HK1222205A1 (zh) 由多能干细胞产生的光感受器和光感受器袓细胞
MX381503B (es) Métodos para la liberación de cromolina.
MX2017005977A (es) Anticuerpos biespecificos y metodos de uso en oftalmologia.
EP3277820A4 (en) Methods for producing modified red blood cell compositions, compositions and uses thereof
MX2023006416A (es) Anticuerpos, usos y metodos.
MX2015014424A (es) Construcciones de proteinas mitocondriales y sus usos.
MX373805B (es) Agonistas de receptor fgf21 y usos del mismo.
EP2811023A4 (en) VECTOR SIMULTANEOUSLY EXPRESSING DODECAMER TRAIL AND SUICIDE HSV-TK GENES, AND ANTICANCER THERAPEUTIC AGENT BASED ON STEM CELLS USING THE SAME
BR112016029632A2 (pt) derivados heteroaromáticos bicíclicos fundidos como inibidores de cinase
BR112016029635A2 (pt) derivados pirazolo-piridina como inibidores de quinase
UY34420A (es) ?métodos de tratamiento del virus de la hepatitis c con que de gs-7977 y ribavirina, composiciones y usos"